Advair faces committee review
The Pulmonary-Allergy Drugs Advisory Committee will convene May 1 to discuss efficacy data from GlaxoSmithKline's sNDA for the approved long-acting beta agonist bronchodilator Advair Diskus (fluticasone propionate/salmeterol). Indicated for the treatment of asthma and chronic obstructive pulmonary disease associated with chronic bronchitis, GSK is seeking expanded labeling that includes data from a 6,100-patient study showing increased survival and reduced exacerbations in COPD patients. GSK is also seeking approval of Advair 500/50 for COPD; the current COPD indication is for Advair 250/50...
You may also be interested in...
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. London, UK-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.